OriGene Technologies Completes $15 Million Offering
OriGene Technologies, Inc., a Rockville, Md. based biosciences company, has completed a $15 million offering, according to a new regulatory filing.
The funding adds to a $16 million series B round completed in 2010 that was led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO.
Earlier this year, OriGene announced that it acquired Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio) to establish a position in the Chinese pathology testing market.
OriGene says that it has one of the largest scale antibody production process facilities in the world while developing gene centric products and services to augment healthcare diagnostics and treatments.
The company is led by CEO and chairman Dr. Wei-Wu, who is also the founder and General Partner of Emerging Technology Partners, a life sciences focused venture fund established in Maryland. Dr. He was also one of the first few employees at Human Genome Sciences, Inc. and from 1993 to 1996 was a scientist at the company. Prior to that he was a Research Fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He has been involved in founding and funding over 20 biotech companies throughout his career. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania.
Video: Dr. Wei-wu He on Development of Assays for Every Human Protein
Citybizlist Partner News
- Rosenberg Martin Greenberg, LLP - Should Technology Reinvent the Classroom?
- Merritt Properties - Greater Baltimore Board of Realtors Signs Lease for Office Space at Merritt’s Timonium Center
- MacKenzie - MacKenzie Commercial Real Estate Recap - April 27th - May 10th, 2013
- St. John Properties - Bill Holzman Promoted to VP, Retail Leasing for St. John Properties